I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The ...